Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prevalence of Positivity for Diabetes-Associated Autoantibodies in Individuals with Type 2 Diabetes and Their Further Characterisation: Cross-sectional Study from Slovakia

M. Rončáková, A. Davani, V. Mikušová, I. Ságová, P. Novodvorský, E. Martinka

. 2023 ; 14 (9) : 1537-1548. [pub] 20230708

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23015367

BACKGROUND: Individuals initially diagnosed with type 2 diabetes (T2D) might exhibit positivity for diabetes-associated autoantibodies (DAA +). We investigated the prevalence of DAA positivity in a group of individuals with T2D who were referred to a tertiary diabetes centre within a pre-specified period of time. We aimed to identify characteristics linked with DAA positivity by comparing DAA + individuals with their DAA-negative counterparts. METHODS: This was a cross-sectional study into which all T2D patients referred to the National Institute of Endocrinology and Diabetology, Ľubochňa, Slovakia, between 1 January and 30 June 2016 were included. Data on > 70 participants' characteristics, including antibodies against glutamic acid decarboxylase (anti-GAD65), insulinoma-associated antigen IA-2 (IA-2A) and insulin (IAA), were collected. RESULTS: Six hundred and ninety-two individuals (387, 55.6% female) with a median (range) age of 62 (24-83) years, HbA1c of 8.9 (5.0-15.7)% [74 (31-148 mmol/mol)] and diabetes duration of 13.0 (0-42) years were analysed. One hundred and forty-five (145/692, 21.0%) tested positive for at least one DAA; 136/692 (19.7%) were positive for anti-GAD65, 21/692 (3.0%) were positive for IA-2A and 9/692 (1.3%) were positive for IAA. Only 84.9% of the DAA + individuals aged > 30 years at the time of diabetes diagnosis met the current diagnostic criteria for latent autoimmune diabetes of adults (LADA). DAA + differed from DAA - individuals in multiple characteristics, including the incidence of hypoglycaemia. CONCLUSION: Several pathological processes linked with distinct types of diabetes can develop in parallel, including insulin resistance and autoimmune insulitis. In this single-centre cross-sectional study from Slovakia, we report a higher than previously published prevalence of DAA positivity in a group of individuals with a formal diagnosis of T2D.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015367
003      
CZ-PrNML
005      
20240918093140.0
007      
ta
008      
231010s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s13300-023-01440-2 $2 doi
035    __
$a (PubMed)37421585
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rončáková, M. $u National Institute of Endocrinology and Diabetology, Ľubochňa, Slovakia $u Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia $7 xx0322713
245    10
$a Prevalence of Positivity for Diabetes-Associated Autoantibodies in Individuals with Type 2 Diabetes and Their Further Characterisation: Cross-sectional Study from Slovakia / $c M. Rončáková, A. Davani, V. Mikušová, I. Ságová, P. Novodvorský, E. Martinka
520    9_
$a BACKGROUND: Individuals initially diagnosed with type 2 diabetes (T2D) might exhibit positivity for diabetes-associated autoantibodies (DAA +). We investigated the prevalence of DAA positivity in a group of individuals with T2D who were referred to a tertiary diabetes centre within a pre-specified period of time. We aimed to identify characteristics linked with DAA positivity by comparing DAA + individuals with their DAA-negative counterparts. METHODS: This was a cross-sectional study into which all T2D patients referred to the National Institute of Endocrinology and Diabetology, Ľubochňa, Slovakia, between 1 January and 30 June 2016 were included. Data on > 70 participants' characteristics, including antibodies against glutamic acid decarboxylase (anti-GAD65), insulinoma-associated antigen IA-2 (IA-2A) and insulin (IAA), were collected. RESULTS: Six hundred and ninety-two individuals (387, 55.6% female) with a median (range) age of 62 (24-83) years, HbA1c of 8.9 (5.0-15.7)% [74 (31-148 mmol/mol)] and diabetes duration of 13.0 (0-42) years were analysed. One hundred and forty-five (145/692, 21.0%) tested positive for at least one DAA; 136/692 (19.7%) were positive for anti-GAD65, 21/692 (3.0%) were positive for IA-2A and 9/692 (1.3%) were positive for IAA. Only 84.9% of the DAA + individuals aged > 30 years at the time of diabetes diagnosis met the current diagnostic criteria for latent autoimmune diabetes of adults (LADA). DAA + differed from DAA - individuals in multiple characteristics, including the incidence of hypoglycaemia. CONCLUSION: Several pathological processes linked with distinct types of diabetes can develop in parallel, including insulin resistance and autoimmune insulitis. In this single-centre cross-sectional study from Slovakia, we report a higher than previously published prevalence of DAA positivity in a group of individuals with a formal diagnosis of T2D.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Davani, Arash, $d 1966- $u National Institute of Endocrinology and Diabetology, Ľubochňa, Slovakia $7 xx0312269
700    1_
$a Mikušová, Veronika $u National Institute of Endocrinology and Diabetology, Ľubochňa, Slovakia $u First Department of Medicine, University Hospital Martin, Martin, Slovakia
700    1_
$a Ságová, Ivana $u National Institute of Endocrinology and Diabetology, Ľubochňa, Slovakia $u Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia
700    1_
$a Novodvorský, Peter $u Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic $u Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK $1 https://orcid.org/0000000232927586 $7 xx0275745
700    1_
$a Martinka, Emil $u National Institute of Endocrinology and Diabetology, Ľubochňa, Slovakia. martinka@nedu.sk $1 https://orcid.org/0000000239428587
773    0_
$w MED00194311 $t Diabetes therapy $x 1869-6953 $g Roč. 14, č. 9 (2023), s. 1537-1548
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37421585 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20240918093135 $b ABA008
999    __
$a ok $b bmc $g 1997116 $s 1201729
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 14 $c 9 $d 1537-1548 $e 20230708 $i 1869-6953 $m Diabetes therapy $n Diabetes Ther $x MED00194311
LZP    __
$a Pubmed-20231010

Najít záznam

Citační ukazatele

Možnosti archivace